Insider filing · RNAC

Timothy A Springer bought $7.4M of Cartesian Therapeutics (RNAC)

Executed Nov 14 2024, disclosed Nov 18 2024, 4 days later.

Over the 21 trading sessions from the disclosed entry session (Nov 18 2024), the stock returned +4.6% (delay-adjusted); from the execution session (Nov 14 2024), +11.2%. Derived: entry at the session's open, exit at the close 20 sessions later.

TS Timothy A Springer Director profile →

Timothy A Springer (Director) filed 11 Form 4 reports in the past 24 months (11 purchases, 0 sales), most often in RNAC. Across 11 priced purchase filings, the average 21-session return was +8.0% from execution and +3.1% from disclosure (delay-adjusted; derived). The largest single filing was $40.0M of TECX (789,294 sh across 2 lots, as filed), executed Feb 5 2025.

RNAC RNAC RNAC · 14 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→